

Treat underlying IBD with positive effects on EIM


- Anti-TNF
- Tofacitinib (UC only)
- Ustekinumab (only arthritis)
- Vedolizumab (only arthritis)

NSAIDs only short-term (COX2)

Treat EIM

- NSAIDs only short-term (COX2)
- Conventional agents (Sulfasalazine, MTX for arthritis)
- Start Anti-TNF
- Consider tofacitinib (UC only) or ustekinumab (only arthritis)

No role for vedolizumab



EN

Treat underlying IBD

- Anti-TNF
- Switch to tofacitinib if disease not controlled (UC only)
- Vedolizumab and ustekinumab might be considered for IBD treatment

Add topical steroids

PG

Treat PG

- Early use of anti-TNF (IFX)
- Switch to tofacitinib only if intestinal inflammation, contraindications for anti-TNF and/or LOR to anti-TNF (in UC only)

No role for vedolizumab and ustekinumab

